Author
Fred Hutch Cancer CenterORCID 0000-0003-4580-649XUnclaimed ORCID profile · follow to get notified of new preprints
3 papers
Recent·Most cited
Shan Li, Kai Song, Huiyun Sun…·John K. Lee
This study reprograms AR-active prostate cancer to NEPC using ASCL1 and NeuroD1, revealing their role in silencing AR and altering chromatin structure.
Sander B. Frank, Thomas W. Persse, I. M. Coleman…·Peter S. Nelson
This study shows that acute CDK12 loss in prostate cancer causes HR deficiency via polyadenylation, but chronic loss leads to adaptation, making PARP inhibitors ineffective and suggesting CDK13 targeting as a new therapeutic approach.
Sumer Jasmine, Rajendra Kumar, Sunghyun Kim…·William Nathaniel Brennen
This paper shows that LSD1 inhibition is effective against neuroendocrine prostate cancer (NEPC) and that combining it with YAP/TEAD inhibition enhances treatment efficacy.